Your AI-Trained Oncology Knowledge Connection!

Opinion

Video

CAR T in Early R/R MM: Advances in Ide-Cel From the KarMMa-3 Trial

Panelists discuss how recent data from the KarMMa-3 study inform the decision to treat early-stage relapsed/refractory multiple myeloma (R/R MM) with idecabtagene vicleucel (ide-cel), including insights from the updated analysis.

Video content above is prompted by the following:

  • How do the recent data from KarMMa-3 inform your decision to treat with ide-cel for early-stage R/R MM?
  • KarMMa-3, updated analysis (online ahead of print):

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!
Related Videos
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
Related Content
The top 5 OncLive videos of the week cover insights in gynecologic cancer, multiple myeloma, urothelial cancer, MPNs, and prostate cancer.
March 23rd 2025

Five Under 5: Top Oncology Videos for the Week of 3/16

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

The top 5 OncLive videos of the week cover insights in colorectal cancer, myeloma, HER2+ breast cancer, and KRAS G12X+ pancreatic ductal adenocarcinoma.
March 16th 2025

Five Under 5: Top Oncology Videos for the Week of 3/9

Paul G. Richardson, MD
October 2nd 2023

Richardson Reviews Findings and Future Directions With Mezigdomide Plus Dexamethasone in R/R Myeloma

Image Credit:© LASZLO– stock.adobe.com
February 28th 2025

CHMP Recommends Subcutaneous Daratumumab Plus VRd for Newly Diagnosed Myeloma

Multiple Myeloma | Image credit: © Nittaya – stock.adobe.com
February 28th 2025

CHMP Recommends Conditional Approval of Linvoseltamab for R/R Multiple Myeloma